Edition:
India

Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics


Monday, 8 Jan 2018 

Jan 8 (Reuters) - Exelixis Inc ::EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS.EXELIXIS INC- AGREEMENT FOR DISCOVERY AND DEVELOPMENT OF NOVEL ONCOLOGY COMPOUNDS TARGETING CASEIN KINASE 1 ALPHA.EXELIXIS INC- WILL PAY STEMSYNERGY UPFRONT PAYMENT OF $3 MILLION AND UP TO $3.5 MILLION IN INITIAL RESEARCH AND DEVELOPMENT FUNDING.EXELIXIS INC- CO WILL BE SOLELY RESPONSIBLE FOR COMMERCIALIZATION OF PRODUCTS THAT ARISE FROM COLLABORATION. 

Company Quote

16.83
-0.53 -3.05%
2:29am IST